BioSpace News Archive

Hoth Therapeutics, Inc. today announced the activation of Washington University School of Medicine in St. Louis as the first clinical site in the CLEER-001 Phase 2a clinical trial of HT-001.

Oragenics, Inc., a biotechnology company dedicated to fighting infectious diseases including COVID-19, announces the appointment of Janet Huffman as Chief Financial Officer, effective March 7, 2023.

Protect Pharmaceutical Corp. “OTC:(PRTT)” announces the change of control of the Preferred series A shares and the appointment of a new president, Ali Yildiz.

Researchers at Boston Children’s Hospital and Harvard Medical School’s Department of Neurobiology have developed a new approach to measure dynamic changes in behavior in an unbiased, observer-independent manner, according to a new study published in and featured on the cover of PAIN, the journal of the International Association for the Study of Pain (IASP).

PACT Pharma, Inc. today announced the publication of a peer-reviewed paper in Nature in collaboration with researchers at University of California, Los Angeles (UCLA) detailing groundbreaking work characterizing and differentiating the immune responses of melanoma patients treated with anti PD-1 immunotherapy.

Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today announced that an article was recently published in Epilepsia showed that perampanel reduces seizures with high effectivity in patients with rare genetic epileptic disease.

Two tissue chip investigations funded by the National Institutes of Health (NIH) are among the payloads launching on SpaceX’s 27th Commercial Resupply Services (CRS) mission to the International Space Station (ISS).

Virscio accelerates investment in advanced histology capabilities to complement in vivo translational R&D service strength

eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the fourth quarter and year ended December 31, 2022 and provided a corporate update.

Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today reported financial results for the fourth quarter and full year ended December 31, 2022.